Cargando…
Design and characterization of anionic PEGylated liposomal formulation loaded with paclitax for ovarian cancer
Despite its strong antitumor activity, paclitaxel (Taxol(®)) has limited clinical applications due to its low aqueous solubility and hypersensitivity caused by cremophor EL and ethanol which is the vehicle used in the current commercial product. In an attempt to develop a pharmaceutically acceptable...
Autores principales: | Makwana, K., Tandel, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3467822/ https://www.ncbi.nlm.nih.gov/pubmed/23066189 http://dx.doi.org/10.4103/0975-7406.94122 |
Ejemplares similares
-
Pegylated liposomal doxorubicin in ovarian cancer
por: Green, Andrew E, et al.
Publicado: (2006) -
Pegylated liposomal doxorubicin in ovarian cancer
por: Strother, Robert, et al.
Publicado: (2009) -
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both
por: Bonaca, Marc P, et al.
Publicado: (2023) -
Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010) -
Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
por: Yuan, Zhen, et al.
Publicado: (2021)